| Medical and Health Sciences | Lifetime | 825 | US 421 | 99.96 |
| Medical and Health Sciences | 2021-2025 | 499 | US 174 | 99.89 |
| Surgery | Lifetime | 143 | US 77 | 99.88 |
| Pulmonary and Respiratory Medicine | Lifetime | 89 | US 47 | 99.88 |
| Rheumatology | Lifetime | 324 | US 145 | 98.63 |
| Cancer Research | Lifetime | 281 | US 151 | 98.35 |
| Oncology | Lifetime | 854 | US 469 | 98.15 |
| Urology | Lifetime | 201 | US 105 | 97.71 |
| Reproductive Medicine | Lifetime | 825 | US 395 | 89.61 |
| Surgery | 2021-2025 | 65 | US 27 | 99.60 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 126 | US 40 | 99.17 |
| Cancer Research | 2021-2025 | 263 | US 94 | 85.41 |
| Oncology | 2021-2025 | 813 | US 349 | 86.64 |
| Rheumatology | 2021-2025 | 495 | US 162 | 71.35 |
| Urological Disorders and Treatments | Lifetime | 19 | US 12 | 99.78 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 21 | US 13 | 99.81 |
| Urinary and Genital Oncology Studies | Lifetime | 11 | US 7 | 99.85 |
| Urologic and reproductive health conditions | Lifetime | 16 | US 14 | 99.84 |
| Renal and related cancers | Lifetime | 32 | US 25 | 99.70 |
| Renal cell carcinoma treatment | Lifetime | 33 | US 26 | 99.75 |
| Prostate Cancer Treatment and Research | Lifetime | 54 | US 39 | 99.75 |
| Testicular diseases and treatments | Lifetime | 18 | US 7 | 99.60 |
| Cancer Genomics and Diagnostics | Lifetime | 148 | US 93 | 99.66 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 71 | US 45 | 99.72 |
| Ferroptosis and cancer prognosis | Lifetime | 85 | US 36 | 98.59 |
| Sarcoma Diagnosis and Treatment | Lifetime | 151 | US 80 | 99.29 |
| Cancer, Lipids, and Metabolism | Lifetime | 181 | US 99 | 99.16 |
| Infectious Disease Case Reports and Treatments | Lifetime | 9 | US 5 | 98.86 |
| Neuroendocrine Tumor Research Advances | Lifetime | 406 | US 165 | 98.53 |
| Peptidase Inhibition and Analysis | Lifetime | 527 | US 244 | 98.15 |
| Epigenetics and DNA Methylation | Lifetime | 986 | US 494 | 97.88 |
| Molecular Biology Techniques and Applications | Lifetime | 386 | US 193 | 97.11 |
| Lung Cancer Research Studies | Lifetime | 688 | US 292 | 97.71 |
| Ovarian cancer diagnosis and treatment | Lifetime | 652 | US 302 | 97.46 |
| Genetic factors in colorectal cancer | Lifetime | 870 | US 365 | 97.27 |
| Neuroblastoma Research and Treatments | Lifetime | 662 | US 325 | 96.80 |
| Cancer Research and Treatments | Lifetime | 963 | US 488 | 95.85 |
| Medical Imaging and Pathology Studies | Lifetime | 855 | US 375 | 96.15 |
| Tuberous Sclerosis Complex Research | Lifetime | 100 | US 59 | 95.28 |
| Soft tissue tumor case studies | Lifetime | 332 | US 172 | 95.62 |
| Genital Health and Disease | Lifetime | 686 | US 308 | 94.75 |
| Sexual Differentiation and Disorders | Lifetime | 735 | US 297 | 95.05 |
| Multiple and Secondary Primary Cancers | Lifetime | 884 | US 379 | 92.15 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 470 | US 111 | 88.03 |
| Chromatin Remodeling and Cancer | Lifetime | 707 | US 324 | 86.30 |
| Gestational Trophoblastic Disease Studies | Lifetime | 651 | US 236 | 84.00 |
| Mechanisms of cancer metastasis | Lifetime | 860 | US 218 | 60.74 |
| Reliability and Agreement in Measurement | Lifetime | 837 | US 313 | 54.21 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 43 | US 21 | 99.32 |
| Urinary and Genital Oncology Studies | 2021-2025 | 33 | US 13 | 99.06 |
| Renal cell carcinoma treatment | 2021-2025 | 79 | US 32 | 98.60 |
| Renal and related cancers | 2021-2025 | 82 | US 41 | 97.14 |
| Prostate Cancer Treatment and Research | 2021-2025 | 209 | US 75 | 97.82 |
| Cancer Genomics and Diagnostics | 2021-2025 | 666 | US 296 | 95.90 |
| Urological Disorders and Treatments | 2021-2025 | 155 | US 33 | 95.38 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 384 | US 114 | 95.98 |
| Urologic and reproductive health conditions | 2021-2025 | 121 | US 24 | 93.04 |
| Epigenetics and DNA Methylation | 2021-2025 | 937 | US 307 | 90.41 |
| Infectious Disease Case Reports and Treatments | 2021-2025 | 12 | US 7 | 87.75 |
| Climate Change and Health Impacts | 2021-2025 | 850 | US 222 | 88.61 |
| Testicular diseases and treatments | 2021-2025 | 145 | US 40 | 87.21 |
| Tuberous Sclerosis Complex Research | 2021-2025 | 232 | US 92 | 65.88 |